FDA, EMA officials say diverse pharmacovigilance strategies, long-term follow-up needed for ATMPs
Regulatory NewsJoanne S. Eglovitch
Advanced therapies/cell and gene therapyChemistry, Manufacturing and Controls (CMC)Clinical TrialsEuropePharmacovigilanceUnited States